Search research articles
Contact Us
Filters
Showing results (1-10 of 21) with videos related to
Page
of 3
Sort By:
Bioorganic & Medicinal Chemistry Letters
|
November 3, 2006
5-HT2C antagonists based on fused heterotricyclic templates: design, synthesis and biological evaluation
Dieter Hamprecht, Fabrizio Micheli, Giovanna Tedesco, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
|
July 13, 2002
Evaluation of the role of intestinal and liver metabolism in the conversion of two different ester prodrugs of sanfetrinem to the parent drug in vitro and in vivo using different rat tissues and a surgically prepared rat model
Simone Braggio, Alessia Ferrara, Matteo Sartori, et al.
Clinical Pharmacokinetics
|
May 4, 2023
Pharmacokinetics and Safety of Cotadutide, a GLP-1 and Glucagon Receptor Dual Agonist, in Individuals with Renal Impairment: A Single-Dose, Phase I, Bridging Study
Gernot Klein, Marcella Petrone, Ye Yang, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
July 16, 2025
From In Vitro Efficacy to Long-Term HbA1c Response for GLP-1R/GlucagonR Agonism Using the 4GI-HbA1c Systems Model
Rolien Bosch, Marcella Petrone, Rosalin Arends, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 1, 2006
Isoindolone derivatives, a new class of 5-HT2C antagonists: synthesis and biological evaluation
Dieter Hamprecht, Fabrizio Micheli, Giovanna Tedesco, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
December 10, 2021
A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP-1 dual agonist
Rolien Bosch, Marcella Petrone, Rosalin Arends, et al.
British Journal of Pharmacology
|
February 25, 2024
Characterisation of cotadutide's dual GLP-1/glucagon receptor agonistic effects on glycaemic control using an in vivo human glucose regulation quantitative systems pharmacology model
Rolien Bosch, Marcella Petrone, Rosalin Arends, et al.
Diabetes, Obesity & Metabolism
|
April 28, 2021
Pharmacokinetics, safety, tolerability and efficacy of cotadutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, in phase 1 and 2 trials in overweight or obese participants of Asian descent with or without type 2 diabetes
Michiko Asano, Akiko Sekikawa, Hyosung Kim, et al.
British Journal of Clinical Pharmacology
|
June 22, 2018
MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study
Philip D Ambery, Sebastian Klammt, Maximillian G Posch, et al.
Diabetologia
|
December 30, 2018
Randomised, phase 1, dose-finding study of MEDI4166, a PCSK9 antibody and GLP-1 analogue fusion molecule, in overweight or obese patients with type 2 diabetes mellitus
Meena Jain, Glenn Carlson, William Cook, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 21) with videos related to
Sort By:
Page
of 3
Bioorganic & Medicinal Chemistry Letters
|
November 3, 2006
5-HT2C antagonists based on fused heterotricyclic templates: design, synthesis and biological evaluation
Dieter Hamprecht, Fabrizio Micheli, Giovanna Tedesco, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
|
July 13, 2002
Evaluation of the role of intestinal and liver metabolism in the conversion of two different ester prodrugs of sanfetrinem to the parent drug in vitro and in vivo using different rat tissues and a surgically prepared rat model
Simone Braggio, Alessia Ferrara, Matteo Sartori, et al.
Clinical Pharmacokinetics
|
May 4, 2023
Pharmacokinetics and Safety of Cotadutide, a GLP-1 and Glucagon Receptor Dual Agonist, in Individuals with Renal Impairment: A Single-Dose, Phase I, Bridging Study
Gernot Klein, Marcella Petrone, Ye Yang, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
July 16, 2025
From In Vitro Efficacy to Long-Term HbA1c Response for GLP-1R/GlucagonR Agonism Using the 4GI-HbA1c Systems Model
Rolien Bosch, Marcella Petrone, Rosalin Arends, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 1, 2006
Isoindolone derivatives, a new class of 5-HT2C antagonists: synthesis and biological evaluation
Dieter Hamprecht, Fabrizio Micheli, Giovanna Tedesco, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
December 10, 2021
A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP-1 dual agonist
Rolien Bosch, Marcella Petrone, Rosalin Arends, et al.
British Journal of Pharmacology
|
February 25, 2024
Characterisation of cotadutide's dual GLP-1/glucagon receptor agonistic effects on glycaemic control using an in vivo human glucose regulation quantitative systems pharmacology model
Rolien Bosch, Marcella Petrone, Rosalin Arends, et al.
Diabetes, Obesity & Metabolism
|
April 28, 2021
Pharmacokinetics, safety, tolerability and efficacy of cotadutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, in phase 1 and 2 trials in overweight or obese participants of Asian descent with or without type 2 diabetes
Michiko Asano, Akiko Sekikawa, Hyosung Kim, et al.
British Journal of Clinical Pharmacology
|
June 22, 2018
MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study
Philip D Ambery, Sebastian Klammt, Maximillian G Posch, et al.
Diabetologia
|
December 30, 2018
Randomised, phase 1, dose-finding study of MEDI4166, a PCSK9 antibody and GLP-1 analogue fusion molecule, in overweight or obese patients with type 2 diabetes mellitus
Meena Jain, Glenn Carlson, William Cook, et al.
Page
of 3